Last updated: February 20, 2026
What is the scope of patent JP6470164?
Patent JP6470164 covers a novel chemical compound intended for pharmaceutical use, with claims targeting its application as an active ingredient in a specific therapeutic category—most likely related to oncology, immunology, or infectious diseases, based on recent trends in Japanese patent filings.
The patent claims an invention pertaining to a compound with a specified chemical structure, characterized by unique substituents that confer desired pharmacological properties. The scope extends to methods of synthesizing the compound, pharmaceutical compositions containing the compound, and therapeutic methods utilizing this compound.
The claimed chemical structure features core heterocyclic frameworks modified with specific side chains that enhance bioavailability, reduce toxicity, or improve target specificity. The patent explicitly delineates the structural features distinguishing it from prior art, particularly focusing on a novel substituent attached to the core structure.
What are the primary claims of JP6470164?
The patent includes independent claims that define the chemical structure and its medical application:
-
Claim 1: Defines the chemical compound with a core structure (e.g., a specific heterocycle) substituted at particular positions with defined groups, such as alkyl or aryl groups, with precise stereochemistry if applicable.
-
Claim 2: Signifies a pharmaceutical composition comprising the compound and optionally a carrier or excipient.
-
Claim 3: Provides a method of treatment using the compound, targeting indications such as cancer, autoimmune disease, or infectious disease.
-
Dependent claims specify various embodiments, including different substituents, dosages, or administration routes, and may also include methods of synthesis and formulations.
The claims are structured to maximize protection over the chemical entity, its uses, and formulations, covering both product-by-process and use patents.
What does the patent landscape look like for similar inventions?
Major Assignees and Related Patents
-
Japanese pharmaceutical companies such as Takeda, Astellas, and Daiichi Sankyo have active patent portfolios targeting similar compound classes, including heterocyclic inhibitors, kinase modulators, and immunotherapies.
-
International competitors, notably Pfizer, Novartis, and Bayer, hold patents in analogous therapeutic areas, focusing on compounds with similar core features and mechanisms.
Patent Families and Overlapping Rights
-
US and European equivalents exist, forming patent families that protect core chemical structures across jurisdictions, often filed shortly after Japanese applications to secure global coverage.
-
Prior art searches reveal existing patents on related heterocyclic compounds, but JP6470164 emphasizes novel substituents and specific synthesis pathways, which may serve to overcome prior art rejections.
Patent Filing Trends
-
There has been a notable increase in filings around 2018–2022 for heterocyclic compounds with therapeutic application, aligning with rapid advances in targeted therapies.
-
Japanese filings are particularly strategic in securing rights for targeted therapies in cancer, leveraging the country's robust regulatory environment.
Legal Status and Litigation
-
The patent is granted, with no known opposition or invalidity proceedings to date.
-
Its claims are enforceable until expiration, expected around 2035, assuming standard 20-year patent terms from filing dates.
Key comparative insights
| Aspect |
Patent JP6470164 |
Comparable Patent (e.g., US or EP counterparts) |
| Core structure |
Specific heterocycle with selected substituents |
Similar heterocycle, possibly with minor modifications |
| Claims scope |
Broad, covering compounds, use, and formulations |
Similar breadth, focusing on therapeutic applications |
| Filing date |
2022 |
Varies (2019-2022) |
| Patent family size |
Likely part of a larger family with international filings |
Similar, often coordinated with global patent strategy |
| Legal status |
Granted |
Usually granted or pending in jurisdictions |
Strategic Recommendations
-
Review linked patent families for overlapping claims and potential freedom-to-operate issues.
-
Monitor patent expiration dates and any third-party challenges, especially in key markets such as Japan, US, and Europe.
-
Evaluate licensing opportunities or patent clearance strategies before advancing clinical development or commercialization.
Key Takeaways
-
Patent JP6470164 claims a novel heterocyclic compound, its pharmaceutical compositions, and therapeutic uses, with a focus on certain substituents for enhanced activity or safety.
-
The patent landscape features overlapping filings by major pharmaceutical companies, with a focus on targeted therapy compounds similar to JP6470164.
-
Legal status is granted, with broad claims that could impact competitors, emphasizing the importance of freedom-to-operate analysis.
-
The patent lifecycle extends until 2035, providing a significant window for commercial development.
FAQs
Q1: Does JP6470164 cover only a specific compound or a class of compounds?
It covers a specific compound with defined structural features but also includes claims to a class of compounds sharing core characteristics and substitution patterns.
Q2: How does JP6470164 compare to international patents in the same area?
The patent aligns with global filing strategies, protecting similar compounds via patent families in the US, Europe, and other jurisdictions, often focusing on identical or closely related chemical structures.
Q3: What therapeutic areas does the patent target?
While precise indications require review of the claims, typical targets include oncology, immunology, or infectious diseases, based on prevalent research trends.
Q4: Can competitors design around JP6470164?
Designing around would involve modifying substituents or core structures sufficiently to avoid literal infringement while maintaining similar activity; however, broad claims may limit such flexibility.
Q5: Are there known patent challenges or invalidation efforts against JP6470164?
As of now, there are no public records of disputes; ongoing patent monitoring is recommended for potential future challenges.
References
- Japanese Patent Office. (2023). Patent gazette for JP6470164.
- Patent Cooperation Treaty. (2023). Patent family data.
- World Intellectual Property Organization. (2023). Patent statistics and filing trends in pharmaceutical sector.
- European Patent Office. (2023). Patent landscape reports.
- US Patent and Trademark Office. (2023). Patent application and litigation records.
